Combining cancer vaccines with immune checkpoint inhibitors (ICIs) such as those targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) is one approach to avoid T cell anergy.237. This evidence concerns the gene CD274 and cancer.